Q-omics provides the consensus-scored FABP12 profile across patient tissues and cancer cell-line models. FABP12 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FABP12 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, FABP12 RNA expression shows 7,333 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where FABP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FABP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FABP12 survival associations across molecular data types. FABP12 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FABP12 RNA expression–survival associations across cancer types. High FABP12 expression shows unfavorable associations in KIRC, LGG, KIRP, UCEC and ACC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FABP12 RNA expression.
This table summarizes FABP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FABP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FABP12 shows lower tumor expression in LUAD, LUSC and HNSC and higher tumor expression in BLCA, UCEC and LIHC. The LUAD box plot shows higher FABP12 RNA expression in normal versus tumor tissue (log2 FC = −0.473, t-test p < 0.001).
This table shows molecular features associated with FABP12 in patient tissues and cancer cell lines. In patient samples, FABP12 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FABP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
